<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874715</url>
  </required_header>
  <id_info>
    <org_study_id>EFC15178</org_study_id>
    <secondary_id>U1111-1197-7811</secondary_id>
    <nct_id>NCT03874715</nct_id>
  </id_info>
  <brief_title>Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine</brief_title>
  <acronym>GEMELLI X</acronym>
  <official_title>Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog® Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate similarity in pharmacokinetics (PK) of SAR341402 and NovoLog after 4x4-week
      periods of alternating administration of SAR341402 and NovoLog compared to 16-week continuous
      use of NovoLog in participants with Type 1 diabetes mellitus also using insulin glargine.

      Secondary Objectives:

        -  To compare the effects of alternating administration of SAR341402 and NovoLog with
           continuous use of NovoLog on immunogenicity.

        -  To evaluate the safety of alternating administration of SAR341402 and NovoLog versus
           continuous use of NovoLog.

        -  To compare other PK parameters between the two treatment arms (alternating
           administration of SAR341402 and NovoLog and continuous use of NovoLog).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration per participant will be less than 19 weeks (for participants who do not
      require the run-in period) and less than 31 weeks (for participants who require the run-in
      period).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Actual">July 8, 2020</completion_date>
  <primary_completion_date type="Actual">July 8, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Similarity in pharmacokinetics (PK) of SAR341402 and NovoLog:AUClast</measure>
    <time_frame>Week 16</time_frame>
    <description>AUClast (area under the time-concentration curve from time zero to the time of the last concentration above the lower limit of quantification) following injection of a predefined, fixed dose of SAR341402 or NovoLog at Week 16</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Similarity in pharmacokinetics (PK) of SAR341402 and NovoLog: AUC</measure>
    <time_frame>Week 16</time_frame>
    <description>AUC (area under the concentration curve) following injection of a predefined, fixed dose of SAR341402 or NovoLog at Week 16</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Similarity in pharmacokinetics (PK) of SAR341402 and NovoLog: Cmax</measure>
    <time_frame>Week 16</time_frame>
    <description>Cmax (maximum concentration) following injection of a predefined, fixed dose of SAR341402 or NovoLog at Week 16</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Number of participants with treatment-emergent anti-insulin aspart antibodies (AIAs)</measure>
    <time_frame>Baseline, Week 8, Week 12 and Week 16</time_frame>
    <description>Number of participants with treatment-emergent AIAs during the 16-week treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Hypoglycemic event</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Number of participants with at least one hypoglycemic event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of hypoglycemic events per participant per year</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Number of hypoglycemic events per participant-year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse Events</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of PK parameters between the two arms (alternating administration of SAR341402 and NovoLog and continuous use of NovoLog)</measure>
    <time_frame>Week 16</time_frame>
    <description>Time to Cmax (Tmax) following injection of a predefined, fixed dose of SAR341402 or NovoLog at Week 16</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Switching arm: Alternative use of SAR341402 and NovoLog</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating use of SAR341402 and NovoLog, self-administered by subcutaneous injection at mealtime, starting with NovoLog for the first 4 weeks, then SAR341402 for 4 weeks, followed by NovoLog for 4 weeks and then SAR341402 for the last 4 weeks on top of Lantus as basal insulin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Switching arm: NovoLog</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous use of NovoLog, self-administrated by subcutaneous injection at mealtime, during the 16-week Treatment Period on top of Lantus as basal insulin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart SAR341402</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
    <arm_group_label>Switching arm: Alternative use of SAR341402 and NovoLog</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
    <arm_group_label>Non-Switching arm: NovoLog</arm_group_label>
    <arm_group_label>Switching arm: Alternative use of SAR341402 and NovoLog</arm_group_label>
    <other_name>NovoLog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine U100</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: Subcutaneous</description>
    <arm_group_label>Non-Switching arm: NovoLog</arm_group_label>
    <arm_group_label>Switching arm: Alternative use of SAR341402 and NovoLog</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Participants with type 1 diabetes mellitus.

          -  Participants on continuous insulin treatment for at least 12 months prior to
             screening.

          -  Participants exclusively on a multiple (≥3) daily injection insulin analogue regimen
             using:

               -  NovoLog as mealtime insulin for at least 12 weeks prior to screening and

               -  Insulin glargine (100 U/mL) as basal insulin for at least 12 weeks prior to
                  screening Note: Participants not meeting this criterion may also qualify,
                  provided that they complete the run-in period during which NovoLog and Lantus
                  will be administered so that, at the time of randomization, the participants have
                  been on NovoLog and insulin glargine (100 U/mL) for at least 12 weeks (including
                  any potential pre-screening administration).

          -  Glycated hemoglobin (HbA1c) below 10% (85.79 mmol/mol) (inclusive) at screening.

          -  Body mass index (BMI) ≤35 kg/m² at screening.

        Exclusion criteria:

          -  Pancreatectomy and/or islet cell transplantation.

          -  Clinically significant laboratory findings, as defined by the protocol.

          -  Known presence of factors that interfere with the HbA1c measurement.

          -  History of severe hypoglycemia requiring emergency room admission or hospitalization
             within 3 months prior to screening.

          -  Hospitalization for recurrent diabetic ketoacidosis within 3 months prior to
             screening.

          -  Retinopathy or maculopathy with one of the following treatments, either recent (within
             3 months of screening) or planned: intravitreal injections or laser or vitrectomy
             surgery.

          -  Use of glucose lowering treatments other than the multiple dose injections (MDI) and
             basal insulin regimen (including use of insulin pump therapy), within 12 weeks prior
             to screening.

          -  Participants having received systemic glucocorticoids for one week or more within 3
             months prior to screening (topical, nasal spray, inhaled or intra-articular
             applications are allowed).

          -  Participants having received systemic immunosuppressive agents within 6 months prior
             to screening.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 8400014</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <zip>92591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400015</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400010</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400029</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708-3346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400038</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400030</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400032</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400026</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400033</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400012</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400005</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400009</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400019</name>
      <address>
        <city>Crystal Lake</city>
        <state>Illinois</state>
        <zip>60012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400028</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400018</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400023</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400003</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852-4267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400013</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400004</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400021</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400031</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400036</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400017</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400007</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400006</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400035</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400034</name>
      <address>
        <city>Jefferson City</city>
        <state>Tennessee</state>
        <zip>37760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400040</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400042</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400027</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400016</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400041</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

